The University of Texas MD Anderson Cancer Center.
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
J Natl Compr Canc Netw. 2020 Feb;18(2):185-217. doi: 10.6004/jnccn.2020.0006.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in recent years because of the improved understanding of the disease biology and the development of novel targeted therapies. In patients with indications for initiating treatment, the selection of treatment should be based on the disease stage, patient's age and overall fitness (performance status and comorbid conditions), and cytogenetic abnormalities. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
慢性淋巴细胞白血病（CLL）和小淋巴细胞淋巴瘤（SLL）的特征是白血病细胞在外周血、骨髓和淋巴组织中进行性积聚。近年来，由于对疾病生物学的认识不断提高和新型靶向治疗方法的发展，CLL/SLL 的治疗方法发生了重大变化。对于有治疗指征的患者，治疗的选择应基于疾病分期、患者年龄和整体健康状况（体能状态和合并症）以及细胞遗传学异常。本文讨论了 NCCN 指南中概述的用于诊断和管理 CLL/SLL 患者的建议。
